Compare Johnson & Johnson (JNJ) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Yum China Holdings Inc — how do they compare? Johnson & Johnson trades at $249.29 (market cap $598.96B), while Yum China Holdings Inc trades at $42.9 (market cap $15.09B). The key difference: Johnson & Johnson is far larger — about 39.7× Yum China Holdings Inc's market cap, and Yum China Holdings Inc pays the higher dividend (2.64%). Which is the better fit depends on your goals.
| JNJ | YUMC | |
|---|---|---|
Market Cap | $598.96B | $15.09B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $267.24 | $57.95 |
52-Week Low | $164.36 | $40.18 |
Enterprise Value | $631.90B | $15.98B |
Dividend Yield | 2.15% | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
YUMC trades at $43.92, up 0.11% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $11.80B in 2025, and profitability remains solid with a 7.83% net margin. The acquisition of Pizza Hut China ownership is a strategic move expected to enhance margins.
The outlook is positive with strong analyst support (73.68% buy ratings), but risks include China's macroeconomic headwinds and competitive pressures. Valuation appears reasonable with a P/E of 16.81, suggesting potential for upside if execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
